Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 3

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 3
---
─

  Holders of our ordinary shares or ADSs may have                                                                        
  difficulty in effecting service of process in the United States or enforcing judgments obtained in the United States.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  As a foreign private issuer whose ADSs are listed                                                                                        
  on the Nasdaq Capital Market, we may follow certain home country corporate governance practices instead of certain Nasdaq requirements.  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  As a foreign private issuer, we are exempt from                                                                                                  

  Any loss of our foreign private issuer status               

  U. S. investors may have difficulty enforcing                                                                                      
  civil liabilities against our company, our directors or members of senior management and the experts named in this Annual Report.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Our quorum requirements to vote at a shareholders                               
  meeting and our voting procedures may not protect our shareholders’ interests.  
 ──────────────────────────────────────────────────────────────────────────────────

Risks Related to Our Business

We have a history of operating losses and may not achieve or
maintain profitability in the future

We have experienced significant recurring operating losses and negative cash flows from operating activities
since inception. For example, for the year ended June 30, 2025,
we had a total comprehensive loss of A$37.88 million and negative cash flows from operating activities of approximately A$36.65 million.
As of June 30, 2025, we had accumulated losses of A$145.73 million.

We are a clinical-stage radiotherapeutics
company that focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical
need. The success of any product development is uncertain.

We expect to continue to incur
losses from operations for the foreseeable future and expect the costs of drug development to increase in the future as more patients
are recruited to our clinical trials. In particular, we expect to continue to incur significant losses in the development of our clinical
trials and drug candidates. Because of the numerous risks and uncertainties associated with the development, manufacturing, sales and
marketing of our drug candidates, we may experience larger than expected future losses and may never become profitable.

Moreover, there is a substantial
risk that we, or our development partners, may not be able to